Archive · 3 Jul 2025
AstraZeneca Weighs US Listing, Threatening London Stock Market
A big company called AstraZeneca, which is worth a lot of money, is thinking about moving where it lists its stocks from London to the United States.
This could be bad news for the London Stock Exchange, possibly making it less important.
The company's boss might be unhappy with UK rules.
This move, if it happens, could show that the UK market has some underlying problems.
AstraZeneca is considering moving its primary listing from London to the US.
The potential move could negatively impact the London Stock Exchange.
AstraZeneca is the most valuable company on the FTSE 100 with a market cap of £161.2 billion.
CEO Pascal Soriot is reportedly frustrated with UK rules.
Experts see the potential shift reflecting deeper structural issues in the UK market.
- Who
- AstraZeneca, investors, the London Stock Exchange.
- What
- AstraZeneca is considering shifting its primary listing from London to the US.
- When
- Not explicitly stated, but recent events.
- Where
- London, UK; potentially the US.
- Why
- Reportedly due to frustration with UK rules, and potential for better valuations and liquidity in the US.
UK Market Supporters
AstraZeneca
Market Implications
UK Market Supporters
Concern over potential loss of a major company listing.
AstraZeneca
Possible benefits of a US listing for AstraZeneca.
- Company
- AstraZeneca
- Market Cap
- £161.2 billion
- Possible Move
- Listing from London to the US
- FTSE 100 Impact
- Potential negative impact
- Reason for consideration
- Frustration with UK rules and higher valuations in the US
